Combination of tamoxifen and D-limonene enhances therapeutic efficacy in breast cancer cells.
Apoptosis
Breast cancer
Combination
D-limonene
Tamoxifen
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
06
04
2023
accepted:
10
06
2023
medline:
3
7
2023
pubmed:
1
7
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
Breast cancer one of the most common diseases in women, has a high death and morbidity rate. Tamoxifen being very much effective in the chemoprevention of breast cancer has been shown to develop resistance during the course of treatment making it difficult for patient's survival. By combining tamoxifen with naturally occurring substances having similar activities, might control the toxicity and increase the susceptibility towards the treatment. As a natural compound, D-limonene has been reported to inhibit the growth of certain malignancies significantly. The main goal of our work is to investigate the combinatorial antitumor effects of D-limonene and tamoxifen in MCF-7 cells, as well as understand the potential underlying anticancer mechanism. MTT assays, colony formation assays, DAPI and Annexin V-FITC labeling, flow cytometer analysis, and western blot analysis were used to explore the details of anticancer mechanism. The combined effects of tamoxifen with D-limonene have shown significant decrease in the cell viability of MCF 7 cells. According to flow cytometer analyses and Annexin V/PI staining, D-limonene has been found to increase tamoxifen-mediated apoptosis as compared to the treatment alone in these cells. Additionally, cell growth has been found to be arrested at G1 phase by regulating cyclin D1 and cyclin B1. Our research consequently provided the first evidence that combining D-limonene and tamoxifen might increase the anticancer efficacy by inducing apoptosis in MCF 7 breast cancer cells. This combinatorial treatment strategy demands more research which might fulfill the need for improved treatment efficacy in controlling breast cancer.
Identifiants
pubmed: 37391551
doi: 10.1007/s12032-023-02081-y
pii: 10.1007/s12032-023-02081-y
doi:
Substances chimiques
Tamoxifen
094ZI81Y45
Limonene
9MC3I34447
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
216Subventions
Organisme : Indian Council of Medical Research
ID : 3/2/2/2/2018/Online Onco Fship/NCD-III
Organisme : Department of Biotechnology, Ministry of Science and Technology, India
ID : BT/BioCARe/08/366/2010-11
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Criscitiello C, Fumagalli D, Saini KS, Loi S. Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. Onco Targets Ther. 2011;4:1.
Chan CC. Selective estrogen receptor modulators. Gynecol Drug Ther. 2016; 105–10
Li Z, Carrier L, Rowan BG. Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells. Mol Cancer Ther. 2008;7:3056–63.
pubmed: 18790785
Yeh W-L, Lin H-Y, Wu H-M, Chen D-R. Combination treatment of tamoxifen with risperidone in breast cancer. PLoS ONE. 2014;9:e98805.
pubmed: 24886861
pmcid: 4041865
Taylor IW, Hodson PJ, Green MD, Sutherland RL. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Can Res. 1983;43:4007–10.
Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, et al. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008;108:421–6.
pubmed: 17541741
Chebet JJ, Ehiri JE, McClelland DJ, Taren D, Hakim IA. Effect of d-limonene and its derivatives on breast cancer in human trials: a scoping review and narrative synthesis. BMC Cancer. 2021;21:1–11.
Mandal D, Parija T. Anticancer mechanism of d-limonene: an updated review and therapeutic possibilities. Curr Cancer Ther Rev. 2022;18:193–201.
Giri RK, Parija T, Das BR. d-limonene chemoprevention of hepatocarcinogenesis in AKR mice: inhibition of c-jun and c-myc. Oncol Rep. 1999;6:1123–30.
pubmed: 10425313
Miller JA, Lang JE, Ley M, Nagle R, Hsu C-H, Thompson PA, et al. Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer limonene in breast cancer. Cancer Prev Res. 2013;6:577–84.
Mandal D, Patel P, Verma SK, Sahu BR, Parija T. Proximal discrepancy in intrinsic atomic interaction arrests G2/M phase by inhibiting Cyclin B1/CDK1 to infer molecular and cellular biocompatibility of d-limonene. Sci Rep. 2022;12:1–14.
Sartippour MR, Pietras R, Marquez-Garban DC, Chen H-W, Heber D, Henning SM, et al. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 2006;27:2424–33.
pubmed: 16785249
Kim YG, Park YH, Yang EY, Park WS, Park KS. Inhibition of tamoxifen’s therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines. Ann Surg Treat Res. 2019;97:230–8.
pubmed: 31742207
pmcid: 6848006
Brüning A, Friese K, Burges A, Mylonas I. Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. Breast Cancer Res. 2010;12:1–11.
Liu Y, Zhang N, Zhang H, Wang L, Duan Y, Wang X, et al. Fatostatin in combination with tamoxifen induces synergistic inhibition in ER-positive breast cancer. Drug Des Dev Ther. 2020;14:3535.
Subramani T, Yeap SK, Ho WY, Ho CL, Osman CP, Ismail NH, et al. Nordamnacanthal potentiates the cytotoxic effects of tamoxifen in human breast cancer cells. Oncol Lett. 2015;9:335–40.
pubmed: 25435988
Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, et al. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules. 2013;18:701–20.
pubmed: 23299550
pmcid: 6269686
Nguyen C, Baskaran K, Pupulin A, Ruvinov I, Zaitoon O, Grewal S, et al. Hibiscus flower extract selectively induces apoptosis in breast cancer cells and positively interacts with common chemotherapeutics. BMC Complement Altern Med. 2019;19:1–14.
Rabi T, Bishayee A. d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: generation of reactive oxygen species and induction of apoptosis. J Carcinog. 2009. https://doi.org/10.4103/1477-3163.51368 .
doi: 10.4103/1477-3163.51368
pubmed: 19465777
pmcid: 2699604
Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y. Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer. 1994;69:1015–20.
pubmed: 8198962
pmcid: 1969414
Reddy D, Sekhar CP. Limonene and BEZ 235 inhibits growth of COLO-320 and HCT-116 colon cancer cells. Int J Drug Deliv. 2016;8:89–95.
Lu X-G, Zhan L-B, Feng B-A, Qu M-Y, Yu L-H, Xie J-H. Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene. World J Gastroenterol. 2004;10:2140.
pubmed: 15237454
pmcid: 4572353
Robinson E, Kimmick GG, Muss HB. Tamoxifen in postmenopausal women. Drugs Aging. 1996;8:329–37.
pubmed: 8935395
Khamis AA, Ali EM, Abd El-Moneim MA, Abd-Alhaseeb MM, El-Magd MA, Salim EI. Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells. Biomed Pharmacother. 2018;105:1335–43.
pubmed: 30021371
Yen C, Zhao F, Yu Z, Zhu X, Li CG. Interactions between natural products and tamoxifen in breast cancer: a comprehensive literature review. Front Pharmacol. 2022;13:847113.
pubmed: 35721162
pmcid: 9201062
Wang L, Tang L, Yao C, Liu C, Shu Y. The synergistic effects of celastrol in combination with tamoxifen on apoptosis and autophagy in MCF-7 cells. J Immunol Res. 2021. https://doi.org/10.1155/2021/5532269 .
doi: 10.1155/2021/5532269
pubmed: 35005034
pmcid: 8739552
Sanaei M, Kavoosi F, Atashpour S, Haghighat S. Effects of genistein and synergistic action in combination with tamoxifen on the HepG2 human hepatocellular carcinoma cell line. Asian Pac J Cancer Prev. 2017;18:2381.
pubmed: 28950682
pmcid: 5720640
Chuang P-Y, Huang C, Huang H-C. The use of a combination of tamoxifen and doxorubicin synergistically to induce cell cycle arrest in BT483 cells by down-regulating CDK1, CDK2 and cyclin D expression. J Pharm Technol Drug Res. 2013;2:12.
Xu Z, Zhao D, Zheng X, Huang B, Xia X, Pan X. Quercetin exerts bidirectional regulation effects on the efficacy of tamoxifen in estrogen receptor-positive breast cancer therapy: an in vitro study. Environ Toxicol. 2020;35:1179–93.
pubmed: 32530119
Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol. 2005;17:559–64.
pubmed: 16098726
To NB, Truong VN-P, Ediriweera MK, Cho SK. Effects of combined pentadecanoic acid and tamoxifen treatment on tamoxifen resistance in MCF-7/SC breast cancer cells. Int J Mol Sci. 2022;23:340.
Jones JL, Daley BJ, Enderson BL, Jin-Rong Z. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrect in T47D breast cancer cells/Discussion. Am Surg. 2002;68:575.
pubmed: 12079141
Ye Z, Liang Z, Mi Q, Guo Y. Limonene terpenoid obstructs human bladder cancer cell (T24 cell line) growth by inducing cellular apoptosis, caspase activation, G2/M phase cell cycle arrest and stops cancer metastasis. J Balk Union Oncol. 2020;25:280–5.
Dai Y, Jin F, Wu W, Kumar SK. Cell cycle regulation and hematologic malignancies. Blood Sci. 2019;1:34–43.
pubmed: 35402801
pmcid: 8975093
Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996;69:92–9.
pubmed: 8608989
Wang L, Wang G, Yang D, Guo X, Xu Y, Feng B, et al. Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression. Mol Med Rep. 2013;8:1279–85.
pubmed: 23969579
Kirkin V, Joos S, Zörnig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta. 2004;1644:229–49.
pubmed: 14996506
Yip K, Reed J. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398–406.
pubmed: 18955968
Rajput S, Kumar BP, Sarkar S, Das S, Azab B, Santhekadur PK, et al. Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS ONE. 2013;8:e61342.
pubmed: 23613836
pmcid: 3629226
Wu F, Shao R, Zheng P, Zhang T, Qiu C, Sui H, et al. Isoalantolactone enhances the antitumor activity of doxorubicin by inducing reactive oxygen species and DNA damage. Front Oncol. 2022;12:81.
Zou P, Chen M, Ji J, Chen W, Chen X, Ying S, et al. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. Oncotarget. 2015;6:36505.
pubmed: 26431378
pmcid: 4742192
Bekele RT, Venkatraman G, Liu R-Z, Tang X, Mi S, Benesch MG, et al. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance. Sci Rep. 2016;6:1–17.
Chatterjee SJ, Pandey S. Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. Cancer Biol Ther. 2011;11:216–28.
pubmed: 21088500
Wang X, Decker CC, Zechner L, Krstin S, Wink M. In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids. BMC Pharmacol Toxicol. 2019;20:1–12.
Siedlakowski P, McLachlan-Burgess A, Griffin C, Tirumalai SS, McNulty J, Pandey S. Synergy of Pancratistatin and Tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria. Cancer Biol Ther. 2008;7:376–84.
pubmed: 18075307